Compare Moderna, Inc. (MRNA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 2.1× Moderna, Inc.'s market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| MRNA | SCHW | |
|---|---|---|
Market Cap | $78.65B | $167.52B |
Volume | 37,373,437 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $225.00 | $113.65 |
52-Week Low | $22.36 | $85.35 |
Typical Hold Time | 59 Days | 85 Days |
Enterprise Value | $74.80B | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Charles Schwab (SCHW) trades at $96.87, up 1.35% with strong fundamentals including 37% net margin and consistent earnings beats. Technical indicators show bearish momentum near key support at $96, while fundamentals reveal robust revenue growth to $23.92B in 2025 and improving cash flow. The company demonstrates operational strength with client assets reaching $13.41T in August 2026 and strategic AI integration with Anthropic.
Outlook remains positive with 56.9% analyst buy ratings and $120.33 consensus target, though near-term technical weakness and competitive pressures pose risks. Earnings momentum and market share gains in the growing e-brokerage sector support upside potential, while interest rate sensitivity and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
